Most of the pharmaceutical co-crystals are formed between drug molecules and small molecular compounds. Here, we demonstrated that small molecular drug griseofulvin and poly (ethylene glycol) can also form co-crystals.
Pharmaceutical co-crystals are usually referred to crystalline 10 molecular complexes formed between drug molecules and other pharmaceutically accepted compounds. 1 In recent years, pharmaceutical co-crystals have received increasing attention as a powerful means to improve the performance of drugs, especially the dissolution rate of poorly-soluble drugs.
2 However, so far 15 most of the pharmaceutical co-crystals are composed of drugs and small molecular co-formers 3 such as succinic acid, nicotinamide, and saccharin. In contrast, co-crystals between drugs and polymers has only been reported in a few cases, including hydroxybenzenes-PEG co-crystals 4,5 and mavacoxib-20 PEG co-crystals 6 , and it would be interesting to see if the drugpolymer co-crystal can be a general structure category and applicable to more drugs.
Here, we report co-crystal formation between small molecular drug griseofulvin (Gris) and polyethylene glycol (PEG) (Fig. 1) . 25 Gris is an antifungal drug, which has three known crystal forms (Form I, II and III) with melting points at 220, 214 and 205 o C, respectively 7 . PEG is a widely used polymer excipient in oral and injection drug products. In fact, Gris has been marked since 1970s in the form of a solid dispersion product as 30 "ultramicrosized griseofulvin" dispersed in PEG matrix 8 , but surprisingly few reports exist on the detailed crystallization behavior of this system.
In our study, a small amount of drug/polymer physical mixture (50/50 w/w, PEG MW 6000, see Supporting Information for 35 details) between two glass cover slips was melted at 220 o C, quenched to predesigned temperatures and then annealed on a hot-stage equipped with a polarized optical microscope. When annealed at temperatures below 100 o C, spherulite crystals formed in the Gris/PEG co-melt. On heating, these crystals 40 melted at about 145 o C, followed by recrystallization into flakelike crystals, which melted above 200 o C (Fig. 2) . Compared with the known melting behavior of Gris crystals in the PEG matrix 9 , the flake-like crystals are identified as Form I of Gris, while the spherulite crystals seemed to be a new crystal form. In contrast, 45 when the sample was annealed at a temperature above 100 o C, the flake Gris crystals formed directly (data not shown). Thermal analysis by differential scanning calorimetry (DSC) confirmed the hot-stage microscope (HSM) observations (Fig. 3) . In the DSC heating scan, Gris/PEG (50/50, w/w) physical mixture showed two endothermal events around 64 o C and 205 o C, corresponding to the melting point of PEG and the depressed 5 melting point of Gris crystals in PEG matrix, respectively, consistent with those observed in literature 9 . However, Gris/PEG co-melt (50/50, w/w) annealed at 60 o C showed an additional endothermal event around 145 o C during the heating scan, which corresponds to the melting behavior of spherulite crystals 10 observed by HSM. Further searching the literature on griseofulvin crystallization, we found that similar phenomena were mentioned by Ford, in which two thermal events of crystallization were also observed in Gris/PEG physical mixtures during heating, but without further investigation on the nature of 15 these phenomena 10 . Powder X-ray diffraction (PXRD) were used to distinguish between different crystal forms (Fig. 4 , all measurements were performed at room temperature). The PXRD pattern of Gris raw material ( Fig. 4b ) was consistent with that of its Form I, and its 20 physical mixture with PEG (50/50, w/w) ( Fig. 4c) showed a simple combination of all the peaks from Gris and PEG. However co-melt of the same composition after annealed at 60 o C showed a different diffraction pattern (Fig. 4d) (Fig. 5) . The same phenomenon was also observed 50 in DSC scans (Fig. S2) . PXRD pattern of the dissociated sample confirmed that, the re-formed product were PEG and Gris Form I (Fig. 4f) . It should be noted that the dissociation occurs only after excess PEG was etched away, while in the PEG matrix, melting of the co-crystal was observed at a higher temperature (Fig.2 and  3 ) 5 The CP/MAS 13 C NMR spectra are used to investigate the state of PEG chains in crystal lattice, as shown in Fig. 6 . The resonance peak of methylene carbon of PEG appeared at 70.8 ppm for pure semi-crystalline PEG and 69.5 ppm for the new crystal form. The upfield shift of PEG resonance peak suggests 10 the chemical environment of PEG chains in this new crystal form is different from that of pure PEG. In addition, the PEG peak of the co-crystal sample is much narrower than that of semicrystalline PEG, suggesting the PEG chains are in a more uniform conformation in the co-crystal 11 . The significant change 15 of chemical shift characteristic of carbon atoms of Gris (e.g., around 57 ppm and 89 ppm) also suggests a different molecular packing mode in the new crystal form, consistent with that observed in PXRD patterns. Solid state NMR spin-lattice relaxation times T 1 ( 1 H) and T 1ρ
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( 1 H) (in the laboratory and rotating frames, respectively) are commonly used to characterize the homogeneity of a mixture 12 . Table 1 shows such relaxation time data of the Gris-PEG cocrystal sample and the two pure components. It can be seen that in the co-crystal sample, the relaxation times of Gris and PEG 25 were different from those of the pure components, and became similar to each other. Using the more sensitive T 1ρ ( 1 H) data for calculation, a common relaxation time around 8-10 ms means that the Gris and PEG molecules are within the distance shorter than the spin diffusion length scale L = (6DT) 0.5 = 2.4 nm, where D is 30 the spin diffusion coefficient (often assumed to be 10 -12 cm 2 /s) and T is the relaxation time 11, 12 . Considering that the molar ratio between Gris and ethylene oxide (EO) units is about 1:2 (hence the PEG weight percent around 20%), and the diameter of a single PEG chain (molecular weight 6000 Da) in its random coil 35 conformation is about 3.6 nm 13 , it is highly unlikely that the PEG chains exist as a separate phase. Instead the Gris and the PEG chains should be homogeneously mixed in the molecular level. More data on the relaxation times are included in the Supporting Information as Table S1 . 40 Since the Gris and the PEG molecules are very different, one likely structure of their co-crystal could be similar to the extensively-studied urea-PEG 14 and cyclodextrin-PEG 15 inclusion complexes, where the packing of the small molecules forms continuous channels and the PEG chain reside within them. Gris 45 is known to form channel-structured solvates with various solvents, including 1,2-dichloroethane, acetonitrile, nitromethane, and nitroethane 16 . Indexing the diffraction pattern of the Gris- possible that the Gris-PEG co-crystal may adopt a crystal structure very similar to that of the Gris-nitroethane (1:1) solvate, but a single crystal sample is still needed to conclusively determine its structure.
Besides the aforementioned experimental conditions, similar 70 Gris-PEG co-crystals were observed in Gris/PEG co-melt under a wide range of conditions, including the variation of annealing temperatures ( Fig. S4 and S5) , compositions (Fig. S6 ) and the molecular weight of PEGs used (Fig. S7) . To investigate the stability of Gris-PEG co-crystal at room temperature, long-time 75 storage (up to 10 months) was carried out, and a slow transformation of co-crystal to separate phases of PEG and Gris was identified by PXRD (Fig. S8) , indicating the co-crystal is a metastable form at room temperature.
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Conclusions
In conclusion, this study demonstrated the co-crystal formation of the small molecular drug griseofulvin and PEG, adding to the short list of drug-PEG co-crystals. Since PEG is widely used in pharmaceutical products, its drug co-crystals should pose no 85 safety restriction to their clinical use. As a pharmaceutical cocrystal co-former, PEG is very different from the conventionally- used small molecules, and hence the dissolution and stability behavior of such drug-polymer co-crystals should be studied. On the other hand, other pharmaceutically-acceptable polymers should also be studied. 
